CUSIP No. 705324 10 1 Page 1 of 6 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 4)1
Pediatrix Medical Group, Inc.
-----------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value
-----------------------------------------------------------------
(Title of Class of Securities)
705324 10 1
-----------------------------------------------------------------
(CUSIP Number)
Welsh, Carson, Anderson Othon A. Prounis, Esq.
& Stowe Reboul, MacMurray, Hewitt,
320 Park Avenue, Suite 2500 Maynard & Kristol
New York, New York 10022 45 Rockefeller Plaza
Attention: Jonathan M. Rather New York, New York 10111
Tel. (212) 893-9500 Tel. (212) 841-5700
-----------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
May 1, 2002
-----------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box
[ ].
- ------------------
1The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page. The information required on
the remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to
all other provisions of the Act.
CUSIP No. 705324 10 1 Page 2 of 6 Pages
1) Name of Reporting Person Welsh, Carson,
and I.R.S. Identification Anderson & Stowe VII, L.P.
No. of Above Person, if
an Entity (Voluntary)
- -----------------------------------------------------------------
2) Check the Appropriate Box (a) [X]
if a Member of a Group (b) [ ]
- -----------------------------------------------------------------
3) SEC Use Only
- -----------------------------------------------------------------
4) Source of Funds Not Applicable
- -----------------------------------------------------------------
5) Check if Disclosure of
Legal Proceedings Is Not Applicable
Required Pursuant to
Items 2(d) or 2(e)
- ------------------------------------------------------------------
6) Citizenship or Place
of Organization Delaware
- ------------------------------------------------------------------
Number of 7) Sole Voting 1,129,755 shares of
Shares Beneficially Power Common Stock
Owned by Each
Reporting Person
---------------------------------------------
8) Shared Voting
Power -0-
---------------------------------------------
9) Sole Disposi- 1,129,755 shares of
tive Power Common Stock
---------------------------------------------
10) Shared Dis-
positive Power -0-
---------------------------------------------
11) Aggregate Amount Beneficially 1,129,755 shares of
Owned by Each Reporting Person Common Stock
- ------------------------------------------------------------------
12) Check if the Aggregate
Amount in Row (11)
Excludes Certain Shares
- ------------------------------------------------------------------
13) Percent of Class
Represented by 4.4%
Amount in Row (11)
- ------------------------------------------------------------------
14) Type of Reporting
Person PN
CUSIP No. 705324 10 1 Page 3 of 6 Pages
1) Name of Reporting Person WCAS Healthcare
and I.R.S. Identification Partners, L.P.
No. of Above Person, if
an Entity (Voluntary)
- -----------------------------------------------------------------
2) Check the Appropriate Box (a) [X]
if a Member of a Group (b) [ ]
- -----------------------------------------------------------------
3) SEC Use Only
- -----------------------------------------------------------------
4) Source of Funds Not Applicable
- -----------------------------------------------------------------
5) Check if Disclosure of
Legal Proceedings Is Not Applicable
Required Pursuant to
Items 2(d) or 2(e)
- ------------------------------------------------------------------
6) Citizenship or Place
of Organization Delaware
- ------------------------------------------------------------------
Number of 7) Sole Voting 57,673 shares of
Shares Beneficially Power Common Stock
Owned by Each
Reporting Person
---------------------------------------------
8) Shared Voting
Power -0-
---------------------------------------------
9) Sole Disposi- 57,673 shares of
tive Power Common Stock
---------------------------------------------
10) Shared Dis-
positive Power -0-
---------------------------------------------
11) Aggregate Amount Beneficially 57,673 shares of
Owned by Each Reporting Person Common Stock
- ------------------------------------------------------------------
12) Check if the Aggregate
Amount in Row (11)
Excludes Certain Shares
- ------------------------------------------------------------------
13) Percent of Class
Represented by 0.2%
Amount in Row (11)
- ------------------------------------------------------------------
14) Type of Reporting
Person PN
CUSIP No. 705324 10 1 Page 4 of 6 Pages
Amendment No. 4 to Schedule 13D (Final Amendment)
-------------------------------------------------
Reference is hereby made to the statement on Schedule 13D filed with
the Commission on May 22, 2001, as amended by Amendment No. 1 thereto filed on
May 29, 2001, Amendment No. 2 thereto filed on August 28, 2001 and Amendment No.
3 thereto filed on November 21, 2001 (as so amended, the "Schedule 13D"). Terms
defined in the Schedule 13D are used herein as so defined.
Item 5 is hereby amended and restated to read in its entirety as
follows:
Item 5. Interest in Securities of the Issuer.
------------------------------------
The following information is based on a total of 25,513,661 shares of
Common Stock outstanding as of April 2, 2002, as reported in the Issuer's
Definitive Proxy Statement on Schedule 14A filed with the Commission on April
15, 2002:
(a)
WCAS VII and VII Partners
-------------------------
WCAS VII owns 1,129,755 shares of Common Stock, or approximately 4.4%
of the Common Stock outstanding. VII Partners, as the general partner of WCAS
VII, may be deemed to beneficially own the securities owned by WCAS VII.
WCAS HP and HP Partners
-----------------------
WCAS HP owns 57,673 shares of Common Stock, or approximately 0.2% of
the Common Stock outstanding. HP Partners, as the general partner of WCAS HP,
may be deemed to beneficially own the securities owned by WCAS HP.
General Partners of VII Partners and HP Partners
------------------------------------------------
(i) Patrick J. Welsh owns 53,668 shares of Common Stock, or
approximately 0.2% of the Common Stock outstanding.
(ii) Russell L. Carson owns 53,668 shares of Common Stock, or
approximately 0.2% of the Common Stock outstanding.
(iii) Bruce K. Anderson owns 53,668 shares of Common Stock, or
approximately 0.2% of the Common Stock outstanding.
(iv) Thomas E. McInerney owns 38,773 shares of Common Stock, or
approximately 0.2% of the Common Stock outstanding.
(v) Robert A. Minicucci owns 17,659 shares of Common Stock, or
less than 0.1% of the Common Stock outstanding.
(vi) Anthony J. deNicola owns 6,864 shares of Common Stock, or less
CUSIP No. 705324 10 1 Page 5 of 6 Pages
than 0.1% of the Common Stock outstanding.
(vii) Paul B. Queally owns 9,736 shares of Common Stock, or less
than 0.1% of the Common Stock outstanding.
(viii) Lawrence B. Sorrel owns 3,195 shares of Common Stock, or less
than 0.1% of the Common Stock outstanding.
(ix) Jonathan M. Rather owns 799 shares of Common Stock, or less
than 0.1% of the Common Stock outstanding.
(b) The general partners of VII Partners and HP Partners may be
deemed to share the power to vote or direct the voting of and to dispose or
direct the disposition of the Common Stock owned by WCAS VII and WCAS HP,
respectively. Each of the general partners of VII Partners and HP Partners
disclaims beneficial ownership of shares of Common Stock other than those he
owns directly or by virtue of his or her indirect pro rata interest, as a
general partner of VII Partners and/or HP Partners, as the case may be, in the
securities owned by WCAS VII and/or WCAS HP.
(c) On May 1, 2002, WCAS VII sold 314,061 shares of Common Stock
on the open market at $45.00 per share. On May 16, 2002 WCAS VII distributed
1,000,000 shares of Common Stock to its partners, including 156,236 shares to
VII Partners. VII Partners immediately distributed such shares to its partners.
(d) Except as described in this statement, no person has the power
to direct the receipt of dividends on or the proceeds of sales of the shares of
Common Stock owned by WCAS VII or WCAS HP.
(e) The Reporting Persons ceased to be the beneficial owners of
more than five percent of the Common Stock on May 16, 2002.
CUSIP No. 705324 10 1 Page 6 of 6 Pages
Signature
---------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
WELSH, CARSON, ANDERSON & STOWE VII, L.P.
By: WCAS VII Partners, L.P.,
General Partner
By: /s/ Jonathan M. Rather
-----------------------------
General Partner
WCAS HEALTHCARE PARTNERS, L.P.
By: WCAS HP Partners, General Partner
By: /s/ Jonathan M. Rather
-----------------------------
Attorney-in-Fact
Dated: May 16, 2002